Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug.

摘要: Abstract A variety of cell biological, pharmacological, crystallographic and clinical approaches have indicated that the antimitotic drug estramustine has interesting unusual properties. Although designed as an alkylating agent, marked stability carbamate linkage to steroid carrier molecule prevents formation intermediates. The affinity parent for microtubule associated proteins concomitant antimicrotube activity cytotoxic consequences in tumor cells. Both preclinical studies combination with other antimicrotubule agents shown this approach great potential achieve therapeutic advantage, especially disease states such hormone refractory prostate cancer.